会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • Visualization of Biological Material by the Use of Coated Contrast Agents
    • 通过使用涂层对比剂可视化生物材料
    • US20100111859A1
    • 2010-05-06
    • US12525389
    • 2008-01-10
    • Oskar AxelssonKajsa Uvdal
    • Oskar AxelssonKajsa Uvdal
    • A61K51/00A61K49/06B05D3/00A61K49/04A61K49/00
    • A61K49/1824A61K49/1848A61K49/186B82Y5/00
    • A method for visualizing biological material, preferably by MRI, comprising the steps of: (i) bringing a population of coated nanoparticles into contact with said biological material, each of which nanoparticles comprises a) a metal oxide of a transition metal, said metal oxide preferably being paramagnetic and preferably comprising a lanthanide (+III) such as gadolinium (+III), and b) a coating covering the surface of the core particle, and (ii) recording the image; wherein the coating is hydrophilic and comprises a silane layer which is located next to the surface of the core particle and comprises one or more different silane groups which each comprises an organic group R and a silane-siloxane linkage where a) R comprises a hydrophilic organic group R′ and a hydrophobic spacer B, b) O is oxygen directly binding to a surface metal ion of the metal oxide, and c) C is carbon and is also part of B. A composition for visualization and methods for the manufacture of the nanoparticles and core particles are also disclosed. Visualization includes imaging by MR, CT, X-ray, near IR fluorescence, PET, microscopying etc with the largest advantages accomplished for in-vivo imaging.
    • 一种用于使生物材料可视化的方法,优选通过MRI显示,其包括以下步骤:(i)使被覆纳米颗粒群与所述生物材料接触,其中每一种纳米颗粒包含a)过渡金属的金属氧化物,所述金属氧化物 优选是顺磁性的,优选包含镧系元素(+ III)如钆(+ III),和b)覆盖核心颗粒表面的涂层,和(ii)记录图像; 其中所述涂层是亲水性的并且包含位于所述核心颗粒表面旁边的硅烷层,并且包含一个或多个不同的硅烷基团,其各自包含有机基团R和硅烷 - 硅氧烷键,其中a)R包含亲水性有机物 基团R'和疏水性间隔物B,b)O是与金属氧化物的表面金属离子直接结合的氧,c)C是碳,也是B的一部分。用于可视化的组合物和用于制备 还公开了纳米颗粒和芯颗粒。 可视化包括MR,CT,X射线,近红外荧光,PET,显微镜等成像,具有体内成像最大的优点。
    • 7. 发明申请
    • Process
    • 处理
    • US20050152840A1
    • 2005-07-14
    • US11002864
    • 2004-12-02
    • Oskar AxelssonCharlotte OlofssonAxel MorgenstjerneGeorg HanssonHaukur JohannessonJan-Henrik Ardenkjaer-Larsen
    • Oskar AxelssonCharlotte OlofssonAxel MorgenstjerneGeorg HanssonHaukur JohannessonJan-Henrik Ardenkjaer-Larsen
    • A61K49/00A61K49/18C07C67/303C07C69/675G01R33/28G01R33/483
    • A61K49/1815
    • The present invention provides a process for the preparation of an MR contrast agent, said process comprising: i) obtaining a solution in a solvent of a hydrogenatable, unsaturated substrate compound and a catalyst for the hydrogenation of said substrate compound; ii) introducing said solution in droplet form into a chamber containing hydrogen gas (H2) enriched in para-hydrogen (p-1H2) and/or ortho-deuterium (o-2H2) whereby to hydrogenate said substrate to form a hydrogenated imaging agent; iii) optionally subjecting said hydrogenated imaging agent to a magnetic field having a field strength below earth's ambient field strength; iv) optionally dissolving said imaging agent in an aqueous medium; v) optionally separating said catalyst from the solution of said imaging agent in said aqueous medium; vi) optionally separating said solvent from the solution of said imaging agent in said aqueous medium; and vii) optionally freezing the solution of said imaging agent in said aqueous medium.
    • 本发明提供了一种制备MR造影剂的方法,所述方法包括:i)获得在可氢化不饱和底物化合物的溶剂中的溶液和用于所述底物化合物氢化的催化剂; ii)将所述液滴形式的溶液引入含有富氢对二氢的氢气(H 2 S 2 H 2)的室中, )和/或邻 - 氘(o-2 H 2 H 2),由此氢化所述底物以形成氢化显像剂; iii)任选地使所述氢化成像剂经受场强低于地球环境场强的磁场; iv)任选地将所述成像剂溶解在水性介质中; v)任选地将所述催化剂与所述显影剂的溶液在所述水性介质中分离; vi)任选地将所述溶剂与所述显影剂的溶液在所述水性介质中分离; 和vii)任选地将所述成像剂的溶液冷冻在所述水性介质中。
    • 8. 发明授权
    • Magnetic resonance imaging
    • 磁共振成像
    • US06574496B1
    • 2003-06-03
    • US09572949
    • 2000-05-18
    • Klaes GolmanOskar AxelssonHaukur Johannesson
    • Klaes GolmanOskar AxelssonHaukur Johannesson
    • A61B505
    • G01R33/5601G01R33/56308
    • A method of magnetic resonance investigation of a sample by (i) reacting ortho-deuterium enriched hydrogen with a hydrogenatable MR imaging agent precursor to produce a hydrogenated (i.e. deuterated) MR imaging agent; (ii) optionally, subjecting the hydrogenated MR imaging agent to a low magnetic field;(iii) administering the hydrogenated MR imaging agent to the sample; (iv) exposing the sample to radiation of a frequency selected to excite nuclear spin transitions of selected non-zero nuclear spin nuclei in said hydrogenated MR imaging agent; (v) detecting magnetic resonance signals of the selected non-zero nuclear spin nuclei from the sample; and (vi) optionally, generating an image or biological functional data or dynamic flow data from the detected signals.
    • 通过(i)使富氘氢与可氢化MR显像剂前体反应以产生氢化(即氘代)MR成像剂,对样品进行磁共振研究的方法; (ii)任选地,使氢化MR成像剂经受低磁场;(iii)向该样品施用氢化MR显像剂; (iv)将所述样品暴露于所选择的用于激发所述氢化MR成像剂中选定的非零核自旋核的核自旋跃迁的频率的辐射; (v)从所述样品检测所选择的非零核自旋核的磁共振信号; 和(vi)可选地,从检测到的信号生成图像或生物功能数据或动态流量数据。
    • 9. 发明授权
    • 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
    • 具有神经营养活性的1-(4-哌啶基) - 苯并咪唑
    • US06180649B2
    • 2001-01-30
    • US09171530
    • 1998-11-19
    • Peter MoldtBjarne Hugo DahlJorgen DrejerOskar Axelsson
    • Peter MoldtBjarne Hugo DahlJorgen DrejerOskar Axelsson
    • A61K31445
    • C07D401/04
    • The present invention discloses compounds of the formula wherein the dotted bonds are optional extra bonds allowing any tautomeric isomers compatible with substituents X and R3; R3 is non-existing, hydrogen, or alkyl; X is O, S, imino, alkoxy, alkylthio, or amino; R1 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, acyl, acylalkyl, alkoxyalkyl, dialkoxyalkyl, or phenylalkyl which may be substituted with alkyl, halogen, amino, nitro or cyano; and R4, R5, R6 and R7 independently of each other are hydrogen; halogen; amino; nitro; CN; CF3; COOH; COO-alkyl; alkyl; acyl; alkoxy; —(CH2)n,—OH wherein n is 0, 1, 2, or 3; —(CH2)m—O-alkyl wherein m is 0, 1,2, or 3; —(CH2)p—O-acyl wherein p is 0, 1,2, or 3; or a pharmaceutically acceptable addition salt thereof. The compounds are useful as pharmaceuticals, for example, in the treatment of traumatic lesions of peripheral nerves, the medulla, and/or the spinal cord, cerebral ischaemic neuronal damage, neuropathy and especially peripheral neuropathy, dementia, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, or any other neurodegenerative disease.
    • 本发明公开了以下结构的化合物:虚线键是任选的额外键,允许与取代基X和R 3相容的任何互变异构体; R3不存在,氢或烷基; X是O,S,亚氨基,烷氧基,烷硫基或 氨基; R 1是氢,烷基,烯基,炔基,环烷基,环烷基烷基,酰基,酰基烷基,烷氧基烷基,二烷氧基烷基或可被烷基,卤素,氨基,硝基或氰基取代的苯基烷基; 和R 4,R 5,R 6和R 7彼此独立地是氢; 卤素; 氨基; 硝基; CN; CF3; COOH; COO-烷基; 烷基; 酰基; 烷氧基 - (CH 2)n,-OH,其中n为0,1,2或3; - (CH 2)m -O-烷基,其中m为0,1,2或3; - (CH 2)p -O-酰基,其中p为0,1,2或3;或其药学上可接受的加成盐。 该化合物可用作药物,例如用于治疗周围神经,髓质和/或脊髓的创伤性损伤,脑缺血性神经元损伤,神经病变,特别是周围神经病变,痴呆,阿尔茨海默病,亨廷顿病,帕金森病 疾病,肌萎缩性侧索硬化或任何其他神经变性疾病。